272
Views
11
CrossRef citations to date
0
Altmetric
Review Article

Difference and alteration in pharmacokinetic and metabolic characteristics of low-solubility natural medicines

, , , , , , & ORCID Icon show all
Pages 140-160 | Received 16 Oct 2017, Accepted 12 Jan 2018, Published online: 01 Feb 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jie Yang, Kailing Li, Dan He, Jing Gu, Jingyu Xu, Jiaxi Xie, Min Zhang, Yuying Liu, Qunyou Tan & Jingqing Zhang. (2020) Toward a better understanding of metabolic and pharmacokinetic characteristics of low-solubility, low-permeability natural medicines. Drug Metabolism Reviews 52:1, pages 19-43.
Read now

Articles from other publishers (10)

Li Yao, Yue-Hong Liu, Xi Zhou, Jia-Hui Yang, Jian-Liang Zhao & Zhi-Yong Chen. (2024) Uptake, tissue distribution, and biotransformation pattern of triclosan in tilapia exposed to environmentally-relevant concentrations. Science of The Total Environment 922, pages 171270.
Crossref
Biao Wang, Hai‐Mei Jiang, Lu‐Ming Qi, Xiang Li, Qun Huang, Xin Xie & Qing Xia. (2023) Deciphering resveratrol's role in modulating pathological pain: From molecular mechanisms to clinical relevance. Phytotherapy Research 38:1, pages 59-73.
Crossref
Shan Gao, Haocheng Zheng, Shujing Xu, Jingwei Kong, Feng Gao, Zhijia Wang, Yuan Li, Ziqi Dai, Xinqi Jiang, Xia Ding & Haimin Lei. (2023) Novel Natural Carrier‐Free Self‐Assembled Nanoparticles for Treatment of Ulcerative Colitis by Balancing Immune Microenvironment and Intestinal Barrier. Advanced Healthcare Materials 12:31.
Crossref
Yufeng Wu, Yang Yang, Jingyu Liu, Yagang Li, Rongbiao Pi, Yu Ren, Tianyang Jiang, Yuran Wang & Guoping Zhong. (2023) Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease. European Journal of Pharmaceutical Sciences 188, pages 106532.
Crossref
Munmun Panda, Surya Kant Tripathi, Gokhan Zengin & Bijesh K. Biswal. (2022) Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers. Cell Biology and Toxicology 39:1, pages 1-31.
Crossref
Yuhe Lei, Meiching Chan, Haiyan Liu, Wenyu Lyu, Lei Chen, Yinqin Zhong, Hua Gan, Mei Wang, Ming Qi, Yu Guo, Junshan Liu & Enxin Zhang. (2022) Evodiamine as the Active Compound of Evodiae fructus to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF-κB Signaling Pathway. Disease Markers 2022, pages 1-20.
Crossref
Chaodan Luo, Jingwen Ai, Erfang Ren, Jianqiang Li, Chunmei Feng, Xinrong Li & Xiaojie Luo. (2021) Research progress on evodiamine, a bioactive alkaloid of Evodiae fructus : Focus on its anti‑cancer activity and bioavailability (Review) . Experimental and Therapeutic Medicine 22:5.
Crossref
Xuemei Xie, Dan He, Yan Wu, Tingting Wang, Cailing Zhong & Jingqing Zhang. 2021. Bio-Carrier Vectors. Bio-Carrier Vectors 57 68 .
Jing Zhao, Yuan Li, Dan He, Xueyuan Hu, Kailing Li, Qiang Yang, Chunshu Fang, Cailing Zhong, Jie Yang, Qunyou Tan & Jingqing Zhang. (2020) Natural Oral Anticancer Medication in Small Ethanol Nanosomes Coated with a Natural Alkaline Polysaccharide. ACS Applied Materials & Interfaces 12:14, pages 16159-16167.
Crossref
Yuru Huang, Xueyuan Hu, Hua Zhao, Dan He, Yi Li, Mei Yang, Zhongshu Yu, Kailing Li & Jingqing Zhang. (2020) Composite alkali polysaccharide supramolecular nanovesicles improve biocharacteristics and anti-lung cancer activity of natural phenolic drugs via oral administration. International Journal of Pharmaceutics 573, pages 118864.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.